T1	Intervention 10 22	enzalutamide
T2	Intervention 281 293	Enzalutamide
T3	Intervention 392 399	placebo
T4	Intervention 570 582	enzalutamide
T5	Intervention 782 805	enzalutamide 160 mg/day
T6	Intervention 814 824	or placebo
T7	Intervention 1655 1671	the enzalutamide
T8	Intervention 1706 1720	in the placebo
T9	Intervention 1834 1876	61 with enzalutamide compared with placebo
T10	Intervention 2012 2044	11·1-13·9) in the enzalutamide
T11	Intervention 2067 2081	(5·5-5·6) in
T12	Intervention 2198 2213	patients in the
T13	Intervention 2227 2237	group than
T14	Intervention 2584 2597	CI 5·6-5·7)
T15	Intervention 2633 2651	months (5·4-5·6)
T16	Intervention 2773 2785	enzalutamide
T17	Intervention 2953 2965	(32%) of 872
T18	Intervention 3009 3017	(37%) of
T19	Intervention 3130 3146	skeletal-related
T20	Intervention 3241 3258	(95% CI 23·9-not
T21	Intervention 3363 3389	improving overall survival
